Upcoming Earnings:
Estimated EPS
---
Estimated Rev
---
• Reported GAAP EPS of -$0.14 up 54.84% YoY • Fulcrum Therapeutics expects the Merger to close in fourth quarter 2026 and expects to declare a $275M aggregate cash dividend to pre-Merger stockholders, subject to adjustment under the Merger Agreement.
Bullish Takeaway
Fulcrum Therapeutics reported $306.5M in cash, cash equivalents, and marketable securities, at least 12 months of expected funding, expected substantial expense decreases, and a planned approximately $7M HbF asset sale.
Bearish Takeaway
Fulcrum Therapeutics ceased active research and development and has no clinical candidates; its Merger remains conditional, and near-term cash outflows include restructuring, facility exit, and transaction-related fees.
Generated by Stocktwits using AI and company-reported earnings data. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|